PAD and CLI patients who show signs of coronary heart disease may benefit from early treatment, according to a new study of nearly 4 million hospitalizations. 

Relying on the AI-powered chatbot for heart assessments could be "dangerous," researchers warn, but the technology may still be helpful in certain situations. 

The three-day event will include sessions about sexual activity among heart patients, depression, energy drinks, stimulants, vaccines and more. The festivities begin Thursday, April 25, in Greece. 

The popular high-fat, low-carb diet is associated with multiple short-term benefits, but they appear to diminish over time. 

Alexander Fanaroff, MD, said the late-breaking BE ACTIVE clinical trial presented at ACC.24 offers a blueprint for how to get patients to be more physically active.

Interventional cardiologist Foluso Fakorede, MD, opened a practice in rural Mississippi, the epicenter of the PAD and CLI epidemic, to try and reverse the glaring health disparities in that region.

The new research, based on data from more than 600 patients, was presented at ACC.24 in Atlanta and published in the New England Journal of Medicine. Semaglutide is sold by Novo Nordisk under the brand name Wegovy.

"I wasn’t expecting these results among women in this lower age group, because we usually see increased risk for heart disease among older women," one cardiologist said. "It was definitely surprising.”